Thu 20 Aug 2026
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Ensure the website is using the HTTPS protocol.
Registered with the Digital Government Authority under number:
| Study Title | Study Sponsor | Status | Study Drug | Trial Phase | Study Protocol Number | Site |
|---|---|---|---|---|---|---|
| Autologous Bone marrow derived osteoblasts in the Management of Avascular Necrosis of the Head of Femur: A Phase II | PI initiated | Rejected | Osteoblasts Stem cells | 2 | 2018-01-315 | King Fahad University Hospital (Al-Khobar) |
| Autologous Bone Marrow Derived Chondrocytes in the Management of Osteoarthritis of Knee: A Phase II Clinical Trial. | PI initiated | Rejected | Chondrocytes Stemcells | 2 | 2018-01-314 | King Fahad University Hospital (Al-Khobar) |
| Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers, An International, Multicenter, Double Blind, Randomized Placebo Controlled Phase 3 trial (ICR-02/ASCOLT) | King Fahad Medical City | Completed | Aspirin | 3 | ICR-02/ASCOLT | KFMC |
| An Open-lable, Randomized, Multi center, Phase III Study to Compare the Saftey and Efficacy of TKI258 Versus Sorafenib in Patients with Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor Therapies" | Novartis | Completed | TKI258 / Sorafenib | 3 | CTKI258A2302 | KFSH & RC-R |
| An Open-lable, Multicenter, Phase 2 Study to Evaluate Everolimus as Monotherapy Treatment for patients with Metastatic Recurrent and/or Unresectable Renall Cell Carcinoma "(EVERMORE). | Novartis | Rejected | RAD001 (Everolimus) | 2 | CRAD001LIC01 | KFSH & RC-R |
| An Open-lable, Multicenter, expanded access study of INC424 for patients with primary myelofibrosis (PMF) or post polycythemia myelofibrosis (PPV MF) or post-essential thrombocythemia myelofibrosis (PET-MF). | Novartis | Completed | INC424 (ruxolitinib) | 3b | CINC424A2401 | NGHA-R |
| AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS | Roche | Terminated | Ocrelizumab | 3b | MN39159 | KFSH&RC-R |
| An Open-Label, Randomized, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in Pediatric Subjects Aged 10 to Less Than 18 Years for the Treatment of Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension | Biogen | Ongoing | Interferon beta-1a | 3 | 105MS306 | KFSH&RC-J |
| An Open-Label, Randomized, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in Pediatric Subjects Aged 10 to Less Than 18 Years for the Treatment of Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension | Biogen | Ongoing | Interferon beta-1a | 3 | 105MS306 | KFSH&RC-J |
| An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus platinum doublet chemotherapy versus platinum doublet chemotherapy in Subjects with Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) | Bristol-Myers Squibb | Terminated | NIVOLUMAB IPILIMUMAB | 3 | CA209-227 | KFSH & RC-R |
Last update date: 08/05/2025 at 03:17 PM Saudi Arabia time
No feedback has been submitted for this page yet.
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.